



# **MEASUREMENT OF CARNITINE IN PRETERM NEONATES SUFFERING RESPIRATORY DISTRESS SYNDROME AND THE EFFECT OF ITS SUPPLEMENTATION**

## **Thesis**

*Submitted for the Fulfillment of the Ph.D. In Childhood Studies  
(Child Health and Nutrition)*

*Presented By*

**MARWA AHMED ABD ELRHEEM**

M.B., B.Ch. M.Sc. Pediatrics  
Ain Shams University

*Under Supervision of*

**Dr. KHALED HUSSEIN TAMAN**

*Professor of Pediatrics  
Institute of Postgraduate Childhood Studies  
Ain Shams University*

**Dr. OSAMA KAMAL ZAKI**

*Consultant of Medical Genetics  
Ain Shams University*

**Dr. MAIESOON SELMY KHEDER**

*Assistant Consultant of Pediatrics  
Al-Galaa Teaching Hospital*

*Institute of Postgraduate Childhood Studies  
Ain Shams University*

**2017**



## Acknowledgments

First and forever, thanks to **Allah**, Almighty for giving me the strength and faith to complete my thesis and for everything else.

I would like to express my sincere gratitude to **Prof. Dr./ Khaled Hussein Taman**, Professor of Pediatrics Institute of Postgraduate Children Studies, Ain Shams University, under his supervision, I had the honor to complete this work, I am deeply grateful to him for his professional advice, guidance and support.

My deep gratitude goes to **Prof. Dr./ Osama Kamal Zaki**, Consultant of Medical Genetics, Ain Shams University, for his valuable efforts and tireless guidance and meticulous supervision throughout this work and for **Dr. Samar Samy**, Chemist in the Genetic Laboratory, for her help and support.

I would like also to thank **Dr./ Maiesoon Selmy Kheder**, Assistant Consultant of Pediatrics, Al-Galaa Teaching Hospital, for the efforts and time she has devoted to accomplish this work with me and for sincere help and support.

Last but not least, I like to thank all my **Family**, and my **dear friends** for their kind help, encouragement and support.

 **Marwa Ahmed**



# Contents

<b>Subject</b>	<b>Page No.</b>
<b>List of Abbreviations .....</b>	<b>i</b>
<b>List of Tables .....</b>	<b>iii</b>
<b>List of Figures .....</b>	<b>v</b>
<b>Introduction .....</b>	<b>1</b>
<b>Aim of the Work.....</b>	<b>3</b>
<b>Review of Literature</b>	
Prematurity.....	5
Respiratory Distress Syndrome .....	29
Carnitine.....	96
<b>Patients and Methods.....</b>	<b>119</b>
<b>Results .....</b>	<b>128</b>
<b>Discussion .....</b>	<b>150</b>
<b>Summary .....</b>	<b>162</b>
<b>Conclusion and Recommendations .....</b>	<b>165</b>
<b>References .....</b>	<b>166</b>
<b>Arabic Summary .....</b>	<b>—</b>

## List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
<b>AAP</b>	: American Academy of Pediatrics
<b>AT</b>	: Antitrypsin
<b>CLD</b>	: Chronic lung disease
<b>COXIs</b>	: Cyclooxygenase inhibitors
<b>CP</b>	: Cerebral palsy
<b>CPAP</b>	: Continuous positive airway pressure
<b>DPPC</b>	: Dipalmitoyl phosphatidylcholine
<b>ELBW</b>	: Extremely low birth weight
<b>FiO<sub>2</sub></b>	: Fractional inspired oxygen
<b>EPT</b>	: Extremely preterm
<b>FRC</b>	: Functional residual capacity
<b>HF</b>	: High-flow nasal cannulae
<b>HFOV</b>	: High-frequency oscillatory ventilation
<b>HMD</b>	: Hyaline membrane disease
<b>LBW</b>	: Low birth weight
<b>LCAD</b>	: Long-chain acyl-CoA dehydrogenase
<b>MCAD</b>	: Medium-chain acyl-CoA dehydrogenase
<b>MV</b>	: Mechanical ventilation
<b>NDI</b>	: Neurodevelopment impairment
<b>NEC</b>	: Necrotizing enterocolitis
<b>NICHD</b>	: National Institute of Child Health and Human Development

<b>NIPPV</b>	: Nasal intermittent positive pressure ventilation
<b>NRN</b>	: Neonatal Research Network
<b>PCVC</b>	: Peripherally inserted central venous catheter
<b>PDA</b>	: Patent ductus arteriosus
<b>PEEP</b>	: Positive end expiratory pressure
<b>PIP</b>	: Peak inspiratory pressure
<b>PPHN</b>	: Persistent Pulmonary hypertension
<b>PPV</b>	: Positive-pressure ventilation
<b>PVR</b>	: Pulmonary vascular resistance
<b>RDS</b>	: Respiratory distress syndrome
<b>ROP</b>	: Retinopathy of prematurity
<b>SCAD</b>	: Short-chain acyl-CoA dehydrogenase
<b>SCHAD</b>	: Short-chain 3-hydroxyacyl-CoA dehydrogenase
<b>SM- score</b>	: Silverman score
<b>SP-D</b>	: Surfactant protein–D
<b>SPSS</b>	: Statistical package for the social science
<b>TPN</b>	: Total parenteral nutrition
<b>V/Q</b>	: Ventilation-perfusion
<b>VLBW</b>	: Very low birth weight
<b>VLCAD</b>	: Very long-chain acyl-CoA dehydrogenase
<b>VPT</b>	: Very preterm

## List of Tables

<b>Table No.</b>	<b>Title</b>	<b>Page No.</b>
<b>Table (1):</b>	Preterm infants' classification by BW .....	6
<b>Table (2):</b>	Risk factors for preterm delivery: .....	8
<b>Table (3):</b>	Neonatal problems associated with premature infants:.....	9
<b>Table (4):</b>	Downes' score .....	61
<b>Table (5):</b>	The Silverman- Anderson retraction score .....	61
<b>Table (6):</b>	ABG score .....	65
<b>Table (7):</b>	Differential diagnosis of RDS .....	74
<b>Table (8):</b>	Target prep-ductal SPO <sub>2</sub> after birth.....	78
<b>Table (9):</b>	Guidelines for monitoring oxygen saturation levels by pulse oximetry.....	82
<b>Table (10):</b>	Ventilatory strategy and indications of mechanical ventilation in RDS .....	85
<b>Table (11):</b>	Causes of Secondary Carnitine Deficiency.....	107
<b>Table (12):</b>	Neonatal Descriptive data of the study and control groups.....	128
<b>Table (13):</b>	Maternal data of the study and control groups .....	131
<b>Table (14):</b>	Laboratory data of the study and control groups .....	132
<b>Table (15):</b>	Comparison between the study and control groups, according to PH value of the blood gases. ....	133

<b>Table (16):</b> Clinical data of the study and control groups .....	134
<b>Table (17):</b> Baseline assessment of Serum Carnitine, of the study and control groups. ....	136
<b>Table (18):</b> Comparison between studied groups regarding neonatal descriptive data.....	137
<b>Table (19):</b> Maternal data of the studied groups .....	138
<b>Table (20):</b> Serum Carnitine level in studied groups before and after supplementation .....	139
<b>Table (21):</b> Clinical data of the studied groups.....	140
<b>Table (22):</b> Mechanical ventilation in studied groups .....	143
<b>Table (23):</b> MV duration in the studied groups. ....	144
<b>Table (24):</b> PH value of the studied groups .....	145
<b>Table (25):</b> Length of hospital stay in the studied groups .....	146
<b>Table (26):</b> Mortality in studied groups .....	147
<b>Table (27):</b> Correlation between serum carnitine and neonatal and maternal data.....	147
<b>Table (28):</b> Linear regression analysis of lower serum carnitine.....	148

## List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (1):</b>	Lung development during the embryonic (A-F) and pseudo glandular (G, H) .....	31
<b>Figure (2):</b>	Lung development canalicular (A), saccular (B), and alveolar stages of organogenesis (C, D) .....	33
<b>Figure (3):</b>	Composition of surfactant .....	35
<b>Figure (4):</b>	Synthesis, recycling and catabolism of lung surfactant. ....	38
<b>Figure (5):</b>	Schematic representation of the complex series of acute and chronic events that lead to neonatal respiratory distress syndrome .....	39
<b>Figure (6):</b>	Pathway of surfactant from the fetal lung to amniotic fluid and some of the factors that can modulate the events .....	40
<b>Figure (7):</b>	Volume-pressure curve showing difference in inflation and deflation volumes at a given pressure (hysteresis) and is due to the presence of surfactant .....	43
<b>Figure (8):</b>	Diffusion of gases across the alveolar–capillary membrane. RBC, red blood cell .....	46
<b>Figure (9):</b>	Photograph of an autopsy specimen demonstrates small at electatic lungs with focal hemorrhage visible on the pleural surface .....	49



<b>Figure (10):</b> Histologic features of RDS show collapsed acini surrounding dilated alveolar ducts lined by smooth homogeneous hyaline membranes.....	50
<b>Figure (11):</b> (A) Model showing the formation of a new liquid bubble at the end of a tube. (B) Graph showing the distending pressure required to maintain the bubble's size (volume) at various stages.....	52
<b>Figure (12):</b> Relationship between gestational age at birth and the incidence of respiratory distress syndrome (RDS).....	55
<b>Figure (13):</b> Specific contributory causes of apnea. CNS, central nervous system .....	60
<b>Figure (14):</b> Carnitine sources and distribution. ....	98
<b>Figure (15):</b> Pathway of L-carnitine synthesis .....	99
<b>Figure (16):</b> The carnitine cycle in fatty acid oxidation.....	101
<b>Figure (17):</b> Fatty acid oxidation during fasting .....	102
<b>Figure (18):</b> Ballard score .....	123
<b>Figure (19):</b> Birth weight of the study and control groups .....	129
<b>Figure (20):</b> Sex distribution of the study and control groups. ....	130
<b>Figure (21):</b> Mode of delivery of the study and control groups.....	130
<b>Figure (22):</b> Maternal age of the study and control groups .....	131
<b>Figure (23):</b> TLC of the study and control groups.....	132

<b>Figure (24):</b> PH value the study and control groups according to PH.....	133
<b>Figure (25):</b> SM score of the study and control groups. ....	134
<b>Figure (26):</b> FIO <sub>2</sub> of the study and control groups.....	135
<b>Figure (27):</b> RD grade of the study and control groups. ....	135
<b>Figure (28):</b> Serum Carnitine of the study and control groups. ....	136
<b>Figure (29):</b> Serum Carnitine level in studied groups before and after supplementation.....	139
<b>Figure (30):</b> SM score in the studied groups.....	141
<b>Figure (31):</b> FIO <sub>2</sub> in the studied groups .....	141
<b>Figure (32):</b> RD grade D1 in the studied groups.....	142
<b>Figure (33):</b> RD grade D7 in the studied groups.....	142
<b>Figure (34):</b> Mechanical ventilation distribution of group A.....	143
<b>Figure (35):</b> Mechanical ventilation distribution of group B. ....	143
<b>Figure (36):</b> Duration of MV in studied groups.....	144
<b>Figure (37):</b> PH value of blood gases in the studied groups. ....	145
<b>Figure (38):</b> Length of hospital stay in the studied groups. ....	146
<b>Figure (39):</b> Odds ratio analysis of lower serum carnitine. ....	149

## **Abstract**

Respiratory distress syndrome (RDS) is among the *most* common diseases of preterm infants. RDS is caused by a decreased production or secretion of pulmonary surfactant. Numerous causes of RDS have been identified, and the factors suspected to be involved in the pathogenesis of RDS are numerous. Carnitine is essential for the fetus and is provided via placental transport. As the gestational age increases, fetal tissues store increasing amounts of carnitine, therefore, preterm infants require exogenous carnitine supplementation for carnitine homeostasis. Treatment with carnitine has shown benefit in the respiratory status of ventilator-dependent adults, as well as stabilization of respiratory parameters and increased physical performance in adult patients with chronic respiratory insufficiency.

**Aim of the work:** The present study was designed to measure the level of free carnitine in preterm neonates with RDS and to evaluate the efficacy of L-carnitine therapy on those neonates.

**Methodology:** Forty preterm infants, including 14 females and 26 males. Study group were divided in to 2 groups, group A: received L-carnitine in a dose of 30 mg/kg/day for 7 days and group B: did not receive supplementation.

### **Results:**

Our results show non statistically significant difference between group A (with Carnitine supplementation) and group B (no supplementation) at day 1. There was statistically significant higher serum carnitine level in group A compared to group B at day 7 (after supplementation). Seven neonates (35%) in group A, and 13(65%) in group B, needed surfactant administration and MV after 24 hs from admission and this difference was statistically significant. Dose of surfactant was statistically significant lower in group A compared to group B ( $P=0.001$ ) and duration of mechanical ventilation was statistically significant lower in group A compared to group B ( $p=0.03$ ).

**Key words:** RDS, Carnitine supplementation, Surfactant, MV

Respiratory distress syndrome (RDS) is the most common threatening respiratory disorder of newborns and it is the most common cause of respiratory failure in the first days after birth. It occurs mainly in preterm neonates (*Jackson et al., 1994*).

RDS occurs as a result of deficiency or absence of surfactant which is very important for lung maturity as it decreases the surface tension of alveoli and keeps the stability of the alveoli, so its absence leads to atelectasis and respiratory distress syndrome (*Moya et al., 1994*).

The incidence and severity of respiratory distress syndrome (RDS), also known as hyaline membrane disease (HMD), are related inversely to the gestational age of the infant. The classic clinical presentation of RDS includes grunting respiration, retractions, nasal flaring, cyanosis, and increased oxygen requirement together with diagnostic radiographic findings and the onset of symptoms shortly after birth (*Rodriguez et al., 2006*).

*Fanaroff et al. (2007)* reported results of the National Institute of Child Health and Human Development (NICHD), neonatal research network study, which showed that rates of RDS were 42%, 71%, 54%, 36%, and 22% in infants weighing 501-1500 g, 501-750 g, 751- 1000g, 1001-1250 g, and 1251-1500 g, respectively.

Surfactant is synthesized and secreted by type II epithelial cells in the alveolus. It is composed primarily of phospholipids; Phosphatidylcholine and phosphatidylglycerol (*Whitsett et al., 2005*).

Carnitine is a small amino acid derivative, plays a major role in fatty acid oxidation as well as in other central metabolic pathways. Fatty acid oxidation is an important energy-providing pathway in early postnatal period. Carnitine has a role not only in energy production, but also as a secondary antioxidant, favoring fatty acid replacement within previously oxidatively damaged membrane phospholipids (*Arenas et al., 1998*).

Carnitine is a naturally occurring hydrophilic amino acid produced endogenously in the kidneys and liver and derived from meat and dairy products in the diet. It plays an essential role in the transfer of long-chain fatty acids into the mitochondria for beta oxidation (*Scaglia, 2006*).

The low levels of L-carnitine present in plasma during pregnancy and the immaturity of liver L-carnitine biosynthetic pathway in preterm neonates may be important determinants in the pathogenesis of respiratory distress syndrome (RDS) (*Arduini et al., 2001*).

Antepartum administration of L-carnitine has been shown to enhance the dipalmitoyl phosphatidylcholine (DPPC) content of fetal rat lung. DPPC is the most important constitute, functionally and quantitatively, of the surfactant complex (*Lohninger et al., 1996*).

Decreased neonatal serum carnitine levels in preterm infants with RDS during the first week of life might be caused by increasing consumption of carnitine in lung tissue for surfactant synthesis (*Ozturk et al., 2006*).

---

## **AIM OF THE STUDY**

---

The aim of the present study was to measure the level of free carnitine in preterm neonates with respiratory distress syndrome (RDS) and to evaluate the effect of its supplementation on them regarding, the respiratory distress course, the duration of mechanical ventilation and the RDS outcome.